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Did	  the	  Dutch	  pneumococcal	  vaccination	  campaign	  decrease	  the	  need	  of	  respiratory	  

















Background	  Streptococcus	  pneumoniae	  causes	  childhood	  respiratory	  mucosal	  infections	  
that	   are	   frequently	   treated	   with	   antibiotics.	   In	   June	   2006,	   an	   infant	   pneumococcal	  
vaccination	  campaign	  (PVC)	  with	  a	  7-­‐valent	  vaccine	  was	  introduced	  in	  the	  Netherlands.	  
In	  2011,	  this	  vaccine	  was	  replaced	  with	  a	  10-­‐valent	  pneumococcal	  vaccine.	  To	  estimate	  
the	   effectiveness	   of	   PVC	   we	   analysed	   the	   respiratory	   antibiotic	   use	   in	   the	   period	   of	  
2002-­‐2012.	  
Methods	   This	   study	   was	   performed	   in	   1-­‐9	   years	   old	   children	   included	   in	   the	   Dutch	  
pharmacy-­‐dispensing	  IADB.nl	  prescription	  database.	  Seasonal	  autoregressive	  integrated	  
moving	  average	  models	  were	  applied	   to	  estimate	   the	  effectiveness	  of	  PVC	   (%)	  and	   its	  
95%	  confidence	  intervals	  (95%CI).	  	  
Results	   The	  models	   showed	   that	   introduction	   of	   the	   7-­‐valent	   PVC	   reduced	   antibiotic	  
prescription	   proportions	   by	   2.8%	   [95%CI	   0.2-­‐5.3]	   and	   5.6%	   [95%CI	   2.3-­‐8.8]	   in	   3	   and	   4	  
years	   old	   children.	  When	   the	   10-­‐valent	   PVC	  was	   added	   to	   the	  models,	   it	   reduced	   the	  
proportion	  of	   antibiotic	  prescriptions	  only	   in	  1	   year	  old	   children	  by	  24.5%	   [95%CI	  6.0-­‐
39.3].	  
Conclusions	   There	   is	   a	   tendency	   towards	   a	   decrease	   in	   respiratory	   antibiotic	  
prescription	   proportions	   after	   the	   introduction	   of	   7-­‐valent	   pneumococcal	   vaccination	  
campaign.	   A	   10-­‐valent	   PVC	   demonstrated	   the	   reduction	   in	   antibiotic	   prescription	  
proportions	   as	   well,	   but	   due	   to	   a	   relatively	   recent	   introduction	   the	   number	   of	   data	  
points	  was	  limited	  and	  therefore	  the	  conclusions	  are	  preliminary.	  	  




In	  2001	   in	  the	  Netherlands,	  45%	  and	  20%	  of	  all	  antibiotics	   in	  children	  were	  prescribed	  
for	  respiratory	  tract	  and	  ear	  infections	  respectively,	  acute	  otitis	  media	  (AOM)	  being	  the	  
leading	   cause	   [1].	   One	   of	   the	   common	   pathogens	   responsible	   for	   these	   diseases,	  
especially	   in	  young	  children,	   is	  Streptococcus	  pneumoniae.	   It	  has	  been	  found	  in	  44%	  of	  
children	   hospitalized	   with	   community-­‐acquired	   lower	   respiratory	   tract	   infections	   [2].	  
Although	  it	  does	  not	  account	  for	  significant	  mortality	  in	  developed	  countries,	  it	  remains	  
a	  public	  health	  concern	  due	  to	  its	  role	  in	  antibiotic	  use	  for	  respiratory	  mucosal	  infections	  
[3].	  
In	   June	   2006	   a	   7-­‐valent	   pneumococcal	   vaccination	   campaign	   was	   introduced	   in	   the	  
Netherlands	  as	  part	  of	   the	  National	  Dutch	   Immunisation	  Programme	  [4].	  Although	  the	  
prescription	  rates	  of	  oral	  antibiotics	   in	  children	  seemed	  to	  decrease	  after	  as	  compared	  
to	  before	  vaccination	  introduction	  [5],	  no	  decline	  in	  ear-­‐nose-­‐throat	  problems	  has	  been	  
observed	   [6].	   The	   latter	   finding	   might	   be	   explained	   by	   the	   pneumococcal	   serotypes	  
replacement:	  a	  decrease	  of	  vaccine-­‐serotype	   invasive	  pneumococcal	  disease	   (IPD)	  was	  
followed	   by	   an	   increase	   in	   IPD	   caused	   by	   non-­‐vaccine	   serotypes	   [7][8].	   There	   is	   no	  
information,	   however,	   on	   changes	   in	   antibiotic	   prescriptions	   that	   are	   usually	   used	   for	  
AOM	  and	  pneumonia	  in	  young	  children	  in	  the	  Netherlands	  after	  as	  compared	  to	  before	  
the	   7-­‐valent	   pneumococcal	   vaccination	   campaign.	   Moreover,	   in	   2011	   the	   7-­‐valent	  
pneumococcal	  vaccine	  was	  replaced	  by	  a	  10-­‐valent	  vaccine	  [9],	  whose	  effects	  have	  not	  
yet	  been	  assessed	  in	  observational	  studies.	  	  
To	   reveal	   the	   patterns	   of	   respiratory	   antibiotic	   prescriptions	   in	   young	   children	   before	  
and	  after	  the	  pneumococcal	  vaccination	  campaigns	  in	  the	  Netherlands	  we	  analysed	  the	  
use	   of	   amoxicillin,	   azithromycin	   and	   cotrimoxazol	   from	   2002	   to	   2012.	   Based	   on	   the	  
Dutch	  general	  practitioner	  guidelines,	   these	  antibiotics	  are	  commonly	  prescribed	   from	  
AOM	  and	  pneumonia	  in	  children	  up	  to	  nine	  years	  of	  age	  in	  general	  practice	  [10,	  11].	  We	  
performed	   descriptive	   and	   time	   series	   analyses	   to	   assess	   whether	   the	   national	  
pneumococcal	   vaccination	   campaign	   reduced	   the	   proportion	   of	   respiratory	   antibiotic	  
prescriptions	  in	  children	  one	  to	  nine	  years	  of	  age.	  




The	   study	   population	   consisted	   of	   one	   to	   nine	   years	   old	   subjects	   from	   the	   IADB.nl	  
database,	  which	  contains	  pharmacy-­‐dispensing	  data	  from	  community	  pharmacies	  in	  the	  
Netherlands.	   A	   more	   detailed	   description	   of	   this	   database	   is	   available	   elsewhere	  
(http://www.iadb.nl/	   and	   [12]).	   The	   main	   outcome	   of	   the	   study	   was	   a	   proportion	   of	  
monthly	   antibiotic	   prescriptions	   in	   a	   particular	   age	   group	   (a	   number	   of	   monthly	  
prescriptions	   in	   the	  age	  group	  per	  month	  divided	  by	  a	  number	  of	   children	   in	   that	  age	  
group	   in	   that	  month).	   The	   aggregated	  measure	   of	   antibiotic	   prescriptions	   per	   year	   (a	  
number	   of	   monthly	   prescriptions	   in	   the	   age	   group	   per	   year	   divided	   by	   a	   number	   of	  
children	   in	   that	  age	  group	   in	   that	   year)	  was	   calculated	  as	  well.	   The	  outcome	  measure	  
was	  based	  on	  prescriptions	  for	  amoxicillin	  (ATC	  code	  J01CA04),	  azithromycin	  (J01FA10)	  
and/or	  cotrimoxazol	   (ATC	  code	  J01EE01)	  as	   these	  are	  standardly	  prescribed	  antibiotics	  
against	  AOM	  and	  pneumonia	  in	  children	  up	  to	  nine	  years	  of	  age	  in	  primary	  care	  [10,	  11].	  
The	   name	   of	   the	   antibiotic	   dispensed,	   ATC	   (Anatomical	   Therapeutical	   Chemical)	  
classification	   [13],	   date	   of	   prescription	   and	   birthdate	   of	   subjects	  were	   extracted	   from	  
the	  IADB.nl	  database.	  	  
The	   study	   period	  was	   from	   January	   2002	   to	  December	   2012.	   It	  was	   chosen	   based	   on	  
some	  preliminary	  analyses:	  we	  excluded	  the	  data	  prior	  to	  2002	  as	  we	  observed	  a	  rapid	  
decrease	  in	  antibiotic	  use	  between	  1995	  and	  2002,	  which	  was	  likely	  due	  to	  policies	  and	  
interventions	  targeted	  at	  decreasing	  the	  antibiotic	  use,	  and	  it	  was	  not	  the	  aim	  to	  assess	  
these	  interventions	  in	  our	  study.	  
The	  main	   study	   intervention	  was	   a	   7-­‐valent	   pneumococcal	   vaccination	   campaign	   that	  
has	  been	   introduced	   in	   the	  Netherlands	   in	   June	  2006	   for	   all	   infants	  born	  after	  1	  April	  
2006.	  We	  also	  assessed	  the	  effects	  of	  a	  10-­‐valent	  pneumococcal	  vaccination	  campaign	  
that	   targeted	   infants	   born	   after	  March	   2011.	   The	   vaccinations	  were	   provided	   at	   two,	  
three,	  four	  and	  eleven	  months	  of	  age	  with	  vaccination	  uptake	  rates	  of	  94-­‐95%	  (van	  Lier,	  
2012).	  We	  modelled	  the	  start	  of	  the	  main	  intervention	  as	  June	  2007,	  as	  we	  anticipated	  
all	  four	  doses	  of	  the	  vaccine,	  including	  the	  booster	  dose,	  to	  have	  been	  administered	  and	  
had	   taken	  an	  effect	  by	   then.	  Because	  of	   few	  data	  points	  available	   in	   the	  dataset	  after	  
the	   introduction	   of	   a	   10-­‐valent	   pneumococcal	   vaccination	   campaign,	  we	   assumed	   the	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start	  of	  the	  10-­‐valent	  pneumococcal	  vaccination	  campaign	  as	  March	  2012,	  and	  not	  May	  
2012,	  which	  might	  exclude	   the	  added	  effect	  of	  a	  booster	  dose.	  Children	  up	   to	  and	  six	  
years	  old	  were	  assumed	   to	  have	   received	  only	   the	  7-­‐valent	   vaccine,	   children	   seven	   to	  
nine	  years	  old	  were	  assumed	  to	  not	  have	  been	  vaccinated	  (potentially	  being	   indirectly	  
protected	  by	   the	   vaccinated	   younger	   age	   groups),	   and	   children	  of	   1	   year	   of	   age	  were	  
assumed	   to	  have	   received	   the	  7-­‐valent	   vaccine	   if	   born	  before	   June	  2006,	   and	   the	   10-­‐
valent	  vaccine	  if	  born	  after	  March	  2011.	  
Statistical	  analysis	  
We	   first	   assessed	   the	  aggregated	  yearly	   respiratory	  antibiotic	  prescription	  proportions	  
from	  2002	  to	  2012	  for	  each	  age	  group	  separately	  by	  plotting	  the	  data.	  We	  then	  assessed	  
monthly	  antibiotic	  prescription	  proportions	  data	  by	  using	  multiplicative	  decomposition	  
[14]	   that	   shows	   the	   observed	   trend	   of	   the	   outcome	   as	   well	   as	   seasonal	   and	   random	  
patterns,	  and	  the	  trend	  after	  removing	  the	  seasonal	  and	  random	  components.	  To	  assess	  
the	   effectiveness	   of	   the	   pneumococcal	   vaccination	   campaign	   we	   used	   seasonal	  
autoregressive	   integrated	  moving	   average	   (SARIMA(p,d,q)(P,D,Q)s)	   time	   series	  models	  
[15]	   with	   intervention	   analysis	   [16],	   where	   p	   and	   P	   is	   the	   number	   of	   auto-­‐regressive	  
components,	  d	  and	  D	  stands	  for	  differencing	  applied	  in	  the	  series,	  q	  and	  Q	  indicates	  the	  
number	   of	   moving	   average	   components,	   and	   s	   is	   equal	   to	   the	   number	   of	   units	   of	  
seasonal	  period	  that	  are	  used	  in	  the	  model	  to	  remove	  additive	  seasonal	  effects.	  SARIMA	  
allows	   us	   to	   estimate	   the	   effect	   of	   an	   intervention	   of	   interest	   by	   taking	   into	   account	  
seasonal	  patterns.	  As	  pneumococcal	  illness	  tends	  to	  occur	  during	  the	  winter	  months,	  we	  
assumed	  seasonal	  patterns	  occurring	  every	  twelve	  months,	  and	  therefore	  s	  was	  set	   to	  
12.	  We	   estimated	   the	   level	   (the	   abrupt	   change)	   in	   antibiotic	   prescription	   proportions	  
and	  the	  change	  in	  trend	  (the	  slope)	  after	  as	  compared	  to	  before	  the	  introduction	  of	  the	  
pneumococcal	  vaccination	  campaigns.	  The	  intervention	  variables	  were	  coded	  as	  0	  until	  
June	  2007	  and	  March	  2012,	  and	  1	  from	  June	  2007	  and	  March	  2012	  onwards	  for	  7-­‐valent	  
and	  10-­‐valent	  pneumococcal	  vaccination	  campaigns	  respectively.	  To	  assess	  the	  change	  
in	   trends	   after	   the	   interventions	   were	   introduced,	   slope	   change	   variables	   coded	   as	   0	  
before	   the	   interventions,	   and	   1	   through	   55	   and	   1	   through	   10	   after	   the	   interventions,	  
respectively	   for	   7-­‐	   and	   10-­‐valent	   vaccination	   campaigns	   were	   created	   [17][18].	   The	  
numbers	  55	  and	  10	  represent	  the	  number	  of	  months	  after	  each	  intervention.	  
Chapter	  3	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The	   best	   SARIMA	   models	   were	   identified	   based	   on	   the	   Akaike	   Information	   Criterion	  
(AIC)	  before	   the	  7-­‐valent	  pneumococcal	  vaccination	  campaign	   took	  place	   for	  each	  age	  
group	  separately	   [19].	  They	  were	   then	  applied	   to	  estimate	   the	  7-­‐valent	  pneumococcal	  
vaccination	   campaign	   effects	   throughout	   the	   post-­‐intervention	   period.	   To	   assess	   the	  
additional	  effect	  of	  the	  10-­‐valent	  pneumococcal	  vaccination	  campaign,	  the	  best	  model	  
(the	  model	   with	   only	   7-­‐valent	   pneumococcal	   vaccination	   campaign	   versus	   the	  model	  
with	  both	  interventions)	  were	  selected	  based	  on	  a	  likelihood	  ratio	  test.	  The	  coefficients	  
and	  their	  standard	  errors	  were	  estimated	  by	  using	  maximum	  likelihood	  estimation.	  The	  
percentage	  of	  change	  and	   its	  confidence	   intervals	  were	  calculated	  as	   (exp(coefficient)-­‐
1)*100%	   and	   (exp(coefficient+/-­‐1.96*standard	   error)-­‐1)*100%.	   The	   adequacy	   of	   each	  
model	  was	   verified	   by	   assessing	   the	   correlograms	   (there	   should	   be	   negligible	   residual	  
autocorrelation)	   and	   the	   plots	   of	   the	   residuals	   (the	   residuals	   of	   the	  model	   should	   be	  
randomly	  scattered).	  The	  analysis	  was	  performed	  with	  R	  2.15.3	  statistical	  software	  [20].	  
Results	  
The	  aggregated	  yearly	  estimates	  revealed	  that	  very	  young	  children,	  in	  particular	  one	  and	  
two	  years	  old,	  had	  the	  most	  prescriptions	  of	  respiratory	  antibiotics	  that	  decreased	  with	  
older	  age	  (Figure	  1).	  We	  observed	  a	  slight	  decrease	  in	  respiratory	  antibiotic	  prescriptions	  
after	   2006	   and	   2011	   pneumococcal	   vaccination	   campaigns	   (Figure	   1).	   We	   observed	  
similar	   patterns	   when	   we	   inspected	   decomposed	   monthly	   trends	   of	   antibiotic	  
prescriptions.	  	  
To	   reveal	   the	   effects	   of	   the	   pneumococcal	   vaccination	   campaign	   on	   the	   antibiotic	  
prescriptions	  we	  performed	  time	  series	  analysis	  from	  2002	  to	  2012.	  The	  best	  time	  series	  
SARIMA	   models	   were	   identified	   based	   on	   AIC	   before	   the	   7-­‐valent	   pneumococcal	  
vaccination	   campaign	   (see	   Table	   1	   for	   the	   best	  models	   for	   every	   age	   group)	   and	   the	  
likelihood	  ratio	  test	  when	  the	  additional	  effect	  of	  a	  10-­‐valent	  pneumococcal	  vaccination	  
campaign	  was	  assessed.	  The	  final	  models	  did	  not	  show	  evidence	  of	  autocorrelation	  and	  
we	  could	  not	  detect	  clear	  patterns	   in	   the	   residual	  autocorrelation	   for	  most	  of	   the	  age	  
groups.	  Only	  the	  model	  for	  the	  4	  years	  old	  children	  showed	  significant	  autocorrelation	  
at	  lag	  12	  indicating	  a	  remaining	  seasonal	  effect.	  However,	  it	  is	  unlikely	  that	  this	  will	  have	  
had	  a	  strong	  effect	  on	  the	  overall	  result.	  




The	   level	  of	  respiratory	  antibiotic	  prescriptions	  decreased	  after	  the	   introduction	  of	  the	  
7-­‐valent	  pneumococcal	  vaccination	  introduction	  in	  most	  of	  the	  age	  groups	  (Table	  1).	  The	  
statistically	   significant	   reduction,	   however,	   was	   only	   present	   in	   3	   and	   4	   years	   old	  
children,	   2.8%	   [95%CI	   0.2-­‐5.3]	   and	   5.6%	   [95%CI	   2.3-­‐8.8]	   respectively.	   The	   month-­‐to	  
month	  trends	  of	  antibiotic	  prescription	  proportions	  were	  similar	  before	  and	  after	  the	  7-­‐
valent	  pneumococcal	  vaccination	  campaign	   in	   five	   to	  nine	  years	  old	  children,	  but	   they	  
showed	  a	  decreasing	  pattern	  (by	  0.2-­‐0.3%)	  in	  one	  to	  four	  years	  old	  children.	  
One	   year	   old	   children	   showed	   a	   significant	   increase	   in	   the	   level	   of	   the	   antibiotic	  
prescription	   proportions	   after	   the	   introduction	   of	   the	   7-­‐valent	   pneumococcal	  
vaccination	   campaign	   (Table	   1).	   Similar,	   but	   not	   significant	   increase	  was	   found	   in	   the	  
two	  years	  old	  children	  as	  well.	  
After	  adding	  the	  10-­‐valent	  pneumococcal	  vaccine	  into	  the	  model,	  the	  level	  of	  antibiotic	  
prescription	   proportions	   in	   one	   year	   old	   children	   increased	   for	   the	   7-­‐valent	  
pneumococcal	   vaccine	   by	   6.2%	   [95%	   CI	   4.0	   to	   8.5%];	   after	   the	   10-­‐valent	   vaccine	  
introduction	  it	  decreased	  by	  24.5%	  [95%	  CI	  6.0	  to	  39.3%].	  The	  month-­‐to-­‐month	  trends	  in	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antibiotic	  prescriptions	  were	  similar	  after	  as	  compared	  to	  before	  the	  introduction	  of	  the	  
7-­‐valent	   (-­‐0.02%	   [95%	   CI	   -­‐0.04	   to	   0.08])	   and	   10-­‐valent	   pneumococcal	   vaccination	  
campaigns	   (2.9%	   [95%	   CI	   -­‐1.54	   to	   7.63]).	   The	   10-­‐valent	   vaccination	   campaign	   did	   not	  
have	  significant	  effects	  in	  other	  age	  groups.	  
	  
Discussion	  
This	  study	  is	  the	  first	  to	  assess	  the	  effects	  of	  the	  7-­‐	  and	  10-­‐valent	  national	  pneumococcal	  
vaccination	   campaigns	   together	   on	   the	   standard	   antibiotic	   prescriptions	   for	   mucosal	  
infections,	  such	  as	  AOM	  and	  pneumonia	  in	  children.	  We	  showed	  that	  there	  was	  a	  slight	  
decrease	  in	  the	  level	  of	  antibiotic	  prescription	  proportions	  after	  the	  introduction	  of	  the	  
7-­‐valent	  pneumococcal	  vaccination	  campaign	  in	  three	  and	  four	  years	  old	  children	  (2.8%	  
and	  5.6%	  respectively),	  but	  not	  in	  one,	  two	  and	  five	  to	  nine	  years	  old	  children.	  When	  we	  
assessed	  the	  effect	  of	  a	  10-­‐valent	  vaccination	  campaign,	  we	  observed	  a	  24%	  decrease	  in	  
the	  level	  of	  antibiotic	  prescription	  proportions	  in	  1	  year	  old	  children,	  while	  there	  was	  no	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effect	   in	   other	   age	   groups.	   Although	   we	   did	   not	   have	   specific	   information	   about	   the	  
causes	   of	   antibiotic	   prescriptions,	   these	   drugs	   are	   specifically	   recommended	   to	   treat	  
AOM	  and	  pneumonia	  in	  young	  children	  in	  the	  Netherlands	  [10,	  11]	  and	  S.pneumoniae	  is	  
one	  of	   the	   leading	  causes	  of	  mucosal	   infections	   [3].	  Therefore	  our	   results	  are	   likely	   to	  
indicate	   the	   effect	   of	   the	   pneumococcal	   vaccination	   campaigns	   on	   health	   problems	  
caused	  by	  S.pneumoniae.	  
We	  found	  that	   in	  very	  young	  children	  the	  antibiotic	  prescription	  proportions	   increased	  
after	   the	   introduction	   of	   the	   7-­‐valent	   pneumococcal	   vaccination	   campaign.	   In	   older	  
children	  the	  point	  estimates	  showed	  a	  decrease,	  but	  it	  was	  only	  significant	  in	  three	  and	  
four	  year	  old	  children.	  The	  not	  significant	  effects	  of	  the	  vaccination	  campaign	  could	  be	  
due	   to	   relatively	   low	   overall	   use	   of	   antibiotics	   in	   the	   Netherlands	   and	   therefore	   it	   is	  
difficult	  to	  obtain	  statistically	  significant	  estimates.	  Moreover,	   it	  has	  been	  documented	  
that	   after	   the	   introduction	  of	   the	   7-­‐valent	   pneumococcal	   vaccination	   campaign	   in	   the	  
Netherlands,	   IPD	  rates	  caused	  by	  non-­‐vaccine	  serotypes	  increased	  [7][8].	  This	  could	  be	  
an	   explanation	   for	   the	   increase	   in	   antibiotic	   prescription	   proportions	   in	   very	   young	  
children	  as	  well	  as	  the	  not	  significant	  differences	  in	  older	  children.	  However,	  in	  our	  study	  
we	  were	  not	  able	  to	  explore	  the	  effect	  of	  serotype	  replacement	  since	  serotype	  specific	  
clinical	  outcome	  data	  was	  not	  part	  of	  the	  dataset.	  	  
We	  found	  a	  24%	  decrease	  in	  one	  year	  old	  children	  after	  the	  introduction	  of	  a	  10-­‐valent	  
pneumococcal	   vaccination	   campaign.	   This	   could	   be	   explained	   both,	   by	   the	   observed	  
increase	   of	   antibiotic	   prescription	   proportions	   after	   the	   7-­‐valent	   pneumococcal	  
vaccination	   campaign,	   and	   by	   a	   better	   effectiveness	   of	   the	   10-­‐valent	   pneumococcal	  
vaccine	  against	  the	  circulating	  serotypes.	  This	  should	  further	  be	  explored	  when	  the	  data	  
on	  more	  data	  points	  and	  for	  more	  age	  groups	  becomes	  available.	  
Because	   pneumococcal	   vaccination	   campaign	   was	   targeting	   well	   defined	   population	  
groups	   at	   the	   national	   level	   at	   well-­‐known	   time	   points	   and	   vaccination	   uptake	   rates	  
were	  high	  (94-­‐95%)	  [4][9],	  we	  were	  able	  to	  study	  the	  effects	  of	  the	  interventions	  on	  the	  
population	  rather	  than	  individual	  level.	  This	  is	  advantageous	  as	  large	  databases	  that	  do	  
not	   include	   individual	  vaccination	   information	  can	  still	  be	  used	  to	  assess	  the	   impact	  of	  
population-­‐based	   interventions.	  By	  using	   SARIMA	   time	   series	  models	  we	  were	  able	   to	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estimate	  direct	  (among	  one	  to	  six	  years	  old	  children)	  and	  indirect	  (among	  seven	  to	  nine	  
years	  old	  children)	  effect	  of	  pneumococcal	  vaccination	  campaigns.	  We	  were	  able	  to	  take	  
seasonal	   effects	   into	   account	   as	   well	   as	   model	   both,	   7-­‐valent	   and	   10-­‐valent	  
pneumococcal	  vaccination	  campaigns.	  	  
In	   conclusion,	   our	   study	   provides	   some	   evidence	   that	   the	   7-­‐valent	   pneumococcal	  
vaccination	  campaign	  was	  effective	  in	  reducing	  antibiotic	  prescriptions,	  especially	  in	  3-­‐4	  
years	  old	  children.	  The	  10-­‐valent	  pneumococcal	  vaccination	  campaign	  demonstrated	  a	  
reduction	   in	  antibiotic	  prescriptions	   in	  one-­‐year-­‐old	  children,	  but	  not	   in	  older	  children.	  
Due	   to	   a	   relatively	   recent	   introduction	   of	   a	   10-­‐valent	   pneumococcal	   vaccination	  
campaign	   the	   number	   of	   data	   points	   was	   limited	   and	   therefore	   the	   conclusions	   are	  
preliminary.	  Future	  studies	  should	  focus	  on	  revealing	  the	  effects	  of	  the	  7-­‐valent	  and	  (the	  
added	  effects	  of)	  the	  10-­‐valent	  pneumococcal	  vaccination	  campaigns.	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